Received date: June 9, 2018; Accepted date: June 29, 2018; Published date: July 3, 2018
Citation: Rosas-Carrasco O, Roa-Rojas P, Martínez-Ruiz A (2018) Sarcopenia, but not sarcopenic obesity, is associated with clinically significant depressive symptoms in older Mexican adults. Clin Psychiatry Vol.4 No.2:5. doi: 10.21767/2471-9854.100053
Copyright: © 2018 Martínez-Ruiz A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Sarcopenia and obesity have a high prevalence in Mexico. Evidence suggests that there is an association between these disorders and clinically significant depressive symptoms.
Objective: The aim of the study is to provide the rate and association of depressive symptoms in subjects with sarcopenia and sarcopenic obesity in elderly Mexican.
Methods: This study is a cross-sectional analysis of data obtained from the FraDySMex study conducted in Mexico City (n=513). Depressive symptoms were assessed with the short version of the Center for Epidemiological Studies- Depression scale, and a cut-off point ≥ 5 indicated the presence of clinically significant depressive symptoms. A body mass index ≥ 30 defined obesity. Sarcopenia was assessed with the SARC-F questionnaire; a score ≥ 4 indicated the presence of sarcopenia. Sarcopenic obesity was defined as obesity along with sarcopenia. Two models were used to determine the association: one model assessed sarcopenia and depressive symptoms; the other one assessed them with sarcopenic obesity.
Results: The analysis included 513 subjects, and the mean age of the subjects was 71.7 ± 9.4; 80.1% were female. The prevalence of CSDS, sarcopenia and sarcopenic obesity was 40.5%, 10% and 7.9%, respectively. Sarcopenia was associated with depressive symptoms (OR 2.64, 95% CI 1.35–5.14, p=0.004), but sarcopenic obesity was not associated with them (OR 1.86, 95% CI 0.89–3.89, p=0.09).
Conclusion: Our study found that subjects with only sarcopenia were more likely to have depressive symptoms than subjects with sarcopenic obesity. However, properly prospective studies are needed to better understand this association.
Sarcopenia; Sarcopenic obesity; Depression
As in other developing countries, the Mexican population is aging. This phenomenon poses urgent concerns for many fields related to public health. In terms of mental health issues, geriatric depression has a prevalence of 1.3% to 5.1% , and the prevalence for clinically significant depressive symptoms (CSDS) in older Mexican adults is up to 29.1% .
There is growing evidence of an association between depression, obesity, and sarcopenia. Currently, obesity is a major health issue in the Mexican population. The prevalence of obesity per the body mass index (BMI) is 32.4%, and the prevalence of obesity per abdominal adiposity is 74%; moreover, the prevalence of these factors has highly increased annually over the past decade . The association between obesity and depression is well known . Longitudinal studies have shown that obesity is a risk factor for the onset of depression and that depression increases the odds of developing obesity . Furthermore, this association is stronger for women than for men .
Likewise, sarcopenia in older Mexican adults has a prevalence of 9.3–20.8% . The data indicate a relationship between depressive symptoms and sarcopenia. A recent study performed by Remigio-Baker and colleagues  found that a low lean muscle mass for locomotion predicts elevated depressive symptoms in men.
The evidence also suggests that there is a synergistic impact of sarcopenia and obesity (sarcopenic obesity) on the risk of depressive symptoms. A study conducted with older Japanese adults found that depressive symptoms were more strongly associated with sarcopenic obesity than in older adults without sarcopenic obesity . Another study  found an association between an adverse psychological health status, such as depressive symptoms and suicidal ideation, and sarcopenic obesity. These findings were confirmed in other studies [11,12]. Furthermore, this synergistic effect has also been confirmed in longitudinal cohort studies. Hamer and colleagues found that after a six-year follow-up time, the onset of new depressive symptoms was associated with the presence of sarcopenic obesity .
Nevertheless, the association between sarcopenia or obesity alone and depressive symptoms is inconclusive. Moreover, evidence exists that suggests that sarcopenia and obesity are not associated with depressive symptoms. For example, a study conducted in older Korean adults did not find an association between sarcopenia, sarcopenic obesity or obesity and depressive symptoms .
Other studies have found an association between sarcopenia and cognitive impairment or depressive symptoms . In a study conducted with Taiwanese men, an association between cognitive impairment, depression and sarcopenia was observed.
The major diagnostic feature of sarcopenia was defined by the loss of muscle mass. However, current definitions from the European Working Group on Sarcopenia in Older People (EWGSOP), the International Working Group on Sarcopenia (IWGS) and the Asian Working Group for Sarcopenia (AWGS), pose that the diagnostic criteria of the sarcopenic syndrome must contain both low muscle mass and impaired muscle function (defined either by muscle strength or physical performance). However, muscle mass and function measurement can be time-consuming and requires specialized equipment, which increases its cost significantly. Hence, current diagnostic methods of sarcopenia can be separated into methods based on objective measures such as dual-energy X-ray absorptiometry, the studies previously cited used this type of methods, and diagnostic methods based on information provided by the subjects such as the SARC-F questionnaire.
The SARC-F questionnaire is a simple and rapid screening instrument for sarcopenia, already validated in several countries, including Mexico. It has shown it can predict physical limitations comparable to the consensus panels EWGSOP, IWGS, and AWGS. Among its many advantages, the sarcopenia diagnosis can be made by minimally trained health personnel and it can be used for large-scale epidemiological studies.
Considering that obesity and sarcopenia have a high prevalence in Mexican populations, a study of the association between these diseases and depressive symptoms is needed. The aim of this study was to analyse the associations between sarcopenia, sarcopenic obesity and depressive symptoms in older Mexican adults.
The current study is a cross-sectional analysis of data obtained in the FraDySMex (Frailty Dynapenia and Sarcopenia in Mexican Adults) cohort study. Details of the study design and participant selection can be found elsewhere . Briefly, the FraDySMex study was a community-based cohort study conducted in Mexico City. The subjects were invited to participate in the study from October 2014 to December 2015. Psychologist or social workers visited them in their homes or in elderly community centers and social security centers. Also, flayers were left outside of churches and health centers. All individuals included in this study were ambulatory, with or without assisting devices and were able to answer the study questionnaire. Isfu bjects obtained a Mini-Mental State Examination (MMSE)s core of 10 points or less, the study questionnaire was answered with the caregivers help. The study included individuals aged 50 years and older and was structured into two phases: October 2014 to December 2014 was the first phase; and October 2015 to December 2015 was the second phase. Each phase included a series of objective geriatric and psychological evaluations. All evaluations were conducted by trained staff, at the Functional Evaluation Research Laboratory at the National Institute of Geriatrics of Mexico (INGer). Subjects who were institutionalized, had any kind of decreased alertness or an acute condition that compromised the ability to answer the questionnaire, were excluded. Written Informed consent was obtained from all participants prior to the study. The current study is a cross-sectional analysis of data collected in the first phase of the FraDySMex study. The subjects included in this analysis had to have the complete data required to conduct this analysis. All subjects were classified into two groups based on the presence of CSDS. The FraDySMex study was approved by the institutional review boards of participant institutions (the Angeles Mocel General Hospital and INGer, DI-PI-002/2014).
Sociodemographic characteristics: The sociodemographic variables evaluated were as follows: age (>50 years old); sex (female versus male); and level of education, which was divided into basic (primary and secondary) education and middle and professional studies (higher education, high school, undergraduate and postgraduate degrees). These categories corresponded to the Mexican education system. Civil status was categorized into a married or de facto relationship and other.
Clinical features: To evaluate the presence of CSDS a short version of the depression scale of the Center for Epidemiologic Studies (CES-D 7), which has been validated in a Mexican elderly population , was used. The CES-D 7 includes seven questions that evaluate five symptoms: three questions for dysphoric mood and one question each for motivation, concentration, loss of pleasure and poor sleep. A cut-off point of5 or more indicated the presence of CSDS .
Obesity was classified baseodn the World Health Organization criteria using the BMI. The BMI was calculated by dividing the body weight by height squared (kg/m2). Individuals with a BMI of 30 or more were considered obese .
Sarcopenia was assessed with the Mexican version of the SARC-F questionnaire. TheS ARC-F questionnaire includes 5 components: strength, walking assistance, sit-to-stand performance, stair climbing and falls. Each question is scored from 0 (no difficulty or 0 falls) to 2 (a lot of difficulty and 4 or more falls). A total score of 4 or more indicates the presence of sarcopenia . Sarcopenic obesity was defined as the presence of obesity with accompanying loss of muscle mass and strength.
It has been reported that the SARC-F reliability (Cronbach alpha of 0.641), sensibility, specificity, positive and negative predictive values are adequate for the sarcopenia diagnosis . Furthermore, high specificity for SARC-F has also been reported in Mexican population (specificity compared to the European Working Group on Sarcopenia in Older People=82.2%, the International Working Group on Sarcopenia=83.3% and the Asian Working Group for Sarcopenia=82.1%). Also, statistically significant correlations between the SARC-F total score and other measures related to sarcopenia like age, quality of life, self-rated health status, cognition, dependence in activities of daily living, nutritional status, depression, gait speed, grip strength, peak torque and power for knee extension, SPPB, balance, SMI, and frailty were found .
A validated version of the MMSE in the Mexican elderly population was used to assess cognitive status. A cut-off point of 24 was used to classify the subjects with or without cognitive impairment .
To evaluate the presence of comorbidity, we used the Spanish version of the Charlson comorbidity index (CCI) . The CCI assesses the presence of 19 diseases, two of which are assessed with and without complications (diabetes and liver disease). The information of the CCI was collected during direct interviews with the individuals or caregiver. For this study, the total score of the CCI was calculated, and a cut-off point of 4 or more was used to classify the results . The presence of gastritis, diabetes with and without complications, and cerebrovascular disease was concluded directly from the CCI .
Physical performance was assessed with the Short Physical Performance Battery (SPPB) score, which combines the evaluation of walking speed, sit-to-stand performance and standing balance. The scores range from 0 (being the worst performance) to 12 (being the best performance). A cut-off point of 9 was used to classify the individuals. All tests were evaluated by qualified medical staff and according to the SPPB instructions. Walking speed was evaluated during a 6-meter walk in the GAIT Rite (platinum 20) instrumented walkway (204 × 35.5 × 0.25 inches, sample rate 100 Hz), positioned along a straight section of the walkway .
Independence was measured with the Barthel Index of Activities of Daily Living tool. This assessment evaluates feeding ability, wheelchair transfers, toilet use, mobility on and off the toilet, bathing, mobility on a level surface, mobility up and down stairs, dressing, bowel control and bladder control. The scores of the index ranges from 0–100 (0 means completely dependent and 100 means completely independent). A cut-off point of ≥ 95 was used to indicate independence .
Polypharmacy refers to the ingestion of many medications and can represent unnecessary medication use. Subjects who ingested 5 or more medications were classified as subjects with polypharmacy .
Statistical analysis: Data were analysed using PASW statistics version 21 (SPSS, Chicago, IL, USA). Descriptive statistics were reported as the means ± standard deviation for continuous variables and as frequencies and percentages for categorical variables. Differences in sociodemographic and clinical features between the groups with and without CSDS were examined using Student’s t-test for continuous variables and the chisquare test for categorical variables.
To evaluate the association between sarcopenia and sarcopenic obesity with CSDS, odds ratios with 95% confidence intervals (CIs) were obtained by conducting a logistic regression analysis. Two final adjusted models are presented. The first model evaluated the association of sarcopenia with CSDS, and the second model evaluated the association of sarcopenic obesity with CSDS. Significant variables for the final models were first selected by a forward selection method and only the variables that showed statistical significance from the initial logistic regression analysis were selected and included in the final models. The level of statistical significance was set at 5%.
A total of 513 individuals were included in the study. The mean age of the study population was 71.7 (SD ± 9.4) years. A total of 37.2% (n=191) were married, 48.8% had a basic education level, and 80.1% (n=411) were women with an average age of 71.7 (SD ± 9.4). The prevalence of CSDS for the whole sample was 40.5% (Table 1). The sociodemographic and clinical characteristics according to the presence of CSDS are shown in Table 2. The prevalence of sarcopenia was 10%, and the prevalence of sarcopenic obesity was 7.9%. Compared to males, females showed a higher rate of CSDS (44.5% vs. 24.5%, respectively, p ≤ 0.001), and individuals with lower levels of education showed higher rates of CSDS (49.8 vs. 31.8, p ≤ 0.001). There was no statistically significant difference in age and marital status. Concerning clinical variables, statistically significant differences of r comorbidity (p=0.04), acid peptic disorder (p ≤ 0.001), diabetes with complications (p=0.009), low physical performance (SPPB) (p=0.04) and cognitive impairment (p ≤ 0.001) were found. Similarly, the presence of sarcopenia (p=0.000) and sarcopenic obesity (p=0.005) showed a statistically significant difference between subjects with CSDS and subjects without CSDS. However, there were no significant differences for obesity (p=0.51).
|Age (years)||71.7 (±9.4)|
|Basic education||249 (48.8)|
|Higher education||261 (51.1)|
|Married/civil union/de facto||191 (37.2)|
|Clinical significant depressive symptoms (CES-D 7 scale ≥ 5)||208 (40.5)|
|Comorbidity (Charlson index ≥ 4)||63 (12.2)|
|Acid peptic disorder (yes)||205 (39.9)|
|Diabetes without complications||100 (19.5)|
|Diabetes with complications (yes)||34 (6.6)|
|Cerebrovascular disease (yes)||11 (2.1)|
|Physical performance (SPPB total score ≤ 9)||237 (46.4)|
|Cognitive impairment (MMSE<24)||67 (13.1)|
|Dependency (Barthel index ≤ 95)||105 (20.5)|
|Polypharmacy (≥ 5 medications)||221 (43.1)|
|Obesity alone group||116 (22.6)|
|Sarcopenia alone group (SARC-F ≥ 4)||48 (10.0)|
|Sarcopenic obesity group||37 (7.96)|
The means and standard deviations are shown for continuous variables. Proportions are shown as percentages for categorical variables. Abbreviations: SD: standard deviation, CES-D: Center for Epidemiological Studies-Depression Scale, MMSE: Mini-mental State Examination, SPPB: Short Physical Performance Battery.
Table 1: Demographic and clinical characteristics of the studied population.
|Age||71.46 (± 8.94)||72.1 (± 10.1)||0.07|
|Basic education||125 (41.3)||124 (59.9)||0.00|
|High/professional education||178 (58.7)||83 (40.1)|
|Married/civil union/de facto||117 (38.6)||74 (35.7)||0.51|
|Other||186 (61.4)||133 (64.3)|
|Female||228 (74.8)||183 (88.0)||0.000|
|Male||77 (25.2)||25 (12.0)|
|Comorbidity (Charlson index ≥ 4)||30 (9.8)||33 (15.9)||0.04|
|Acid peptic disorder (yes)||97 (31.8)||108 (51.9)||0.000|
|Diabetes without complications||60 (19.7)||40 (19.2)||0.90|
|Diabetes with complications (yes)||13 (4.3)||21 (10.1)||0.009|
|Cerebrovascular disease (yes)||5 (1.6)||6 (2.9)||0.33|
|SPPB battery total score ≤ 9||152 (50.2)||85 (41.1)||0.04|
|Cognitive impairment (MMSE<24)||30 (6.6)||37 (12.5)||0.009|
|Dependency (Barthel index ≤ 95)||54 (17.7)||51 (24.5)||0.06|
|Polypharmacy (≥ 5 medications)||131 (43.2)||90 (43.5)||0.95|
|Obesity alone||72 (23.6)||44 (21.2)||0.51|
|Sarcopenia alone||18 (5.9)||30 (14.4)||0.000|
|Sarcopenic obesity||15 (4.9)||22 (10.6)||0.005|
The means and standard deviation are shown for continuous variables. Proportions are shown as percentages for categorical variables. P values for group differences were calculated with Student’s t-test for continuous variables and with the chi-squared test for categorical variables. Abbreviations: MMSE: Mini-mental State Examination, SPPB: Short Physical Performance Battery.
Table 2: Comparison of demographic and clinical characteristics of the study participants with and without depressive symptoms.
The logistic regression analysis for CSDS according to the presence of sarcopenia and sarcopenic obesity are shown in Table 3. These models are adjusted per significant sociodemographic variables (gender and education) and the other variables that showed statistical significance (comorbidity, gastritis, diabetes with complications, low physical performance and cognitive impairment). The sarcopenic analysis model showed that men had a lower risk of presenting with CSDS than women (OR 0.4; 95% CI 0.29-0.83). The model also showed that individuals with higher education had less risk of presenting with CSDS (OR 0.5; 95% CI 0.38-0.87). Subjects with low physical performance and diabetes with complications showed a significative risk of presenting with CSDS (OR 1.08; 95% CI 0.71– 1.64 and OR 2.4; 95% CI 1.08-5.42, respectively). Additionally, the presence of sarcopenia was associated with having CSDS (OR 2.64; 95% CI 1.35–5.14). Meanwhile, the sarcopenic obesity model (Table 3), did not found a significant association between sarcopenic obesity and the presence of CSDS (OR 1.86; 95% CI 0.89-3.89).
|Unadjusted model||Model 1
Adjusted Model for Sarcopenia
Adjusted Model for SO
|Female (vs. male)||0.40||0.24-0.66||0.000||0.49||0.29-0.83||0.009||0.55||0.32-0.96||0.03|
|Higher education (vs. basic education)||0.47||0.32-0.67||0.000||0.57||0.38-0.87||0.009||0.51||0.34-0.77||0.002|
|Married (vs. not married)||0.88||0.61-1.23||0.51||-||-||-||-||-||-|
|High comorbidity (vs. low comorbidity)||1.72||1.01-2.93||0.04||1.48||0.79-2.80||0.21||1.18||0.62-2.25||0.59|
|Acid peptic disorder (vs. no)||2.31||1.61-3.33||0.000||1.83||1.21-2.74||0.004||1.99||1.32-3.00||0.001|
|Diabetes without complications (vs. no)||0.97||0.62-1.51||0.90||-||-||-||-||-||-|
|Diabetes with complications (vs. no)||2.52||1.23-5.16||0.01||2.42||1.08-5.42||0.03||2.42||1.02-5.71||0.04|
|Cerebrovascular disease (vs. no)||1.48||0.35-6.28||0.59||-||-||-||-||-||-|
|Poor physical performance (vs. no)||0.69||0.48-0.98||0.04||1.08||0.71-1.64||0.71||0.96||0.63-1.46||0.85|
|Cognitive impairment (vs. no)||2.03||1.10-3.75||0.02||1.71||0.94-3.10||0.07||1.49||0.85-2.71||0.18|
|Dependent (vs. independent)||0.93||0.54-1.58||0.79||-||-||-||-||-||-|
|Polypharmacy (vs. no)||0.74||0.47-1.16||0.19||-||-||-||-||-||-|
(vs. without sarcopenia)
(vs. without sarcopenic obesity)
|Hosmer & Lemeshow=0.90||Hosmer & Lemeshow=0.91||Hosmer & Lemeshow= 0.89|
Abbreviations; OR: Odds ratio, CI: confidence interval, CSDS: Clinically Significant Depressive Symptoms, SO: Sarcopenic Obesity.
Table 3: Unadjusted and Adjusted Models for Sarcopenia, Sarcopenic Obesity and other factors associated with CSDS.
In the current study, our main goal was to analyse the relationship between sarcopenia, sarcopenic obesity and CSDS symptoms in older Mexican adults. We expected CSDS to be highly prevalent, and we hypothesized that CSDS would be related to sarcopenia and sarcopenic obesity. However, we found an association between CSDS and sarcopenia but not between CSDS and sarcopenic obesity.
The association between depression and sarcopenia has been previously reported. The study conducted by Remigio-Baker and colleagues  showed that according to the scores from the CESD scale, the depressive symptoms of Chinese men were associated with lower muscle mass, particularly in the muscles used for locomotion. These findings were similar to the results of an English longitudinal study that included 3862 community dwelling participants. The authors also found an association between sarcopenia and the onset of depressive symptoms. These findings were particularly marked in the obese subjects at the study baseline .
Two main hypotheses have been proposed to explain these findings. The first states that the muscle mass system is implicated in the mental health outcome of wellbeing through adequate glucose regulation . The second hypothesis states that an elevated presence of cortisol is related to increases in inflammatory markers that may promote decreased muscle mass. Therefore, both hypotheses suggest a pathological cycle between the loss of muscular mass and the presence of depressive symptoms. However, the data remains inconclusive.
Regarding sarcopenic obesity and its association with CSDS, we predicted that we would find a statistically significant association between sarcopenic obesity and CSDS, we did not find such an association. There are three possible explanations for our findings. First, the association between sarcopenic obesity and depressive symptoms may not be synergistic. Second, obesity alone is not necessarily associated with depression. Third, evidence suggests that the Mexican population have a misperception of BMI.
Regarding the first explanation, evidence of the association between sarcopenic obesity and the presence of CSDS is inconclusive. For example, Ishii and colleagues  suggest that sarcopenic obesity, but not sarcopenia or obesity alone, is associated with depressive symptoms. Additionally, in a longitudinal study, Hamer and colleagues  found that depressive symptoms were associated with sarcopenic obesity. However, another study found positive associations between self-stress perception and sarcopenic obesity and between suicidal ideation and sarcopenic obesity; there was no association between CSDS and sarcopenic obesity.
Because other studies have shown that obesity alone is not necessarily associated with depression, our second explanation may partially explain our findings. For example, a 16-year followup cohort French study reported that depressive symptoms were associated with obesity if the subjects also had poor metabolic health (evaluated through cardiovascular risk factors) . Although the mechanisms that explain the association between obesity and CSDS remain unclear.
The “jolly fat” hypothesis states the opposite association between obesity and CSDS. A Brazilian study showed that subjects with severe obesity had a similar incidence of depressive symptoms to that of subjects with a normal BMI during a 4-year follow-up period. However, the prevalence of CSDS was higher in the subjects with severe obesity . Moreover, Qian and colleagues  found an inverse association between obesity and depressive symptoms. They suggested a partial explanation: obese people do not have strict diets and are therefore less likely to present depressive symptoms.
Third, our findings can also be explained by misperception of BMI. Some studies show that underestimating or overestimating BMI can be associated with the presence or absence of depressive symptoms . Heard and colleagues  found that underestimating weight was associated with a higher quality of life. Considering that Mexico has one of the highest rates of obesity in the world, underestimating a person’s weight could explain our results . A study conducted with 32050 Mexican subjects reported that up to 58% of the subjects underestimated their BMI . Thus, underestimation of weight can lead to a lower frequency of depressive symptoms.
However, since obesity is a complex and multifactorial disease, it is important to consider the possibility that its association with other diseases such as depression may be different depending on the context. If we want to clarify the association between obesity and depression, more studies that consider it as a multifactorial phenomenon are needed.
This study has several limitations that should be acknowledged. First, due to the nature of cross-sectional studies, the temporality of the phenomena cannot be considered for analysis. Second, the sample size is limited and cannot be generalized to the older population as a whole. Third, the SARC-F questionnaire is a valid instrument for diagnosing sarcopenia, however, the diagnosis is based on information provided by the subjects rather than on objective measures such as dual-energy X-ray absorptiometry. Therefore, properly conducted prospective studies with larger samples are needed for a better understanding of this association.
The authors thank the participants and their relatives and the staff of FraDySMex study.
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2019 All rights reserved. iMedPub LTD Last revised : September 16, 2019